Ballmann M, Conlon J M
Diabetologia. 1985 Jun;28(6):355-8. doi: 10.1007/BF00283143.
Rats with streptozotocin-induced diabetes of 10 weeks' duration showed significant changes in the total content of somatostatin, substance P and vasoactive intestinal polypeptide in the stomach and small intestine compared with control animals. An increase (p less than 0.05) in the concentration and total content of gastric somatostatin and a decrease (p less than 0.05) in the concentration and content of gastric substance P were seen in the streptozotocin-treated rats. The increase in the vasoactive intestinal polypeptide (VIP) content (54%, p less than 0.05) and the decrease in the substance P content (35%, p less than 0.05) of the gut may contribute to the impaired intestinal motility observed in animals with experimentally produced diabetes. Both the diabetogenic effect of streptozotocin and the changes in regulatory peptide concentrations were prevented by injection of nicotinamide before streptozotocin suggesting that the changes did not arise from a non-specific toxic effect of streptozotocin upon gastrointestinal neurones and/or endocrine cells.
与对照动物相比，链脲佐菌素诱导糖尿病病程达10周的大鼠，其胃和小肠中生长抑素、P物质和血管活性肠肽的总含量出现显著变化。在链脲佐菌素处理的大鼠中，观察到胃生长抑素的浓度和总含量增加（p<0.05），胃P物质的浓度和含量降低（p<0.05）。肠道血管活性肠肽（VIP）含量增加（54%，p<0.05）和P物质含量降低（35%，p<0.05）可能导致实验性糖尿病动物出现肠道运动障碍。在链脲佐菌素注射前注射烟酰胺可预防链脲佐菌素的致糖尿病作用以及调节肽浓度的变化，这表明这些变化并非由链脲佐菌素对胃肠神经元和/或内分泌细胞的非特异性毒性作用引起。
